194 related articles for article (PubMed ID: 7494233)
41. Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide.
Kleinberg L
Core Evid; 2012; 7():115-30. PubMed ID: 23118709
[TBL] [Abstract][Full Text] [Related]
42. Interstitial brachytherapy versus cytoreductive surgery in recurrent malignant glioma.
Ryken TC; Hitchon PW; VanGilder JC; Wen BC; Jani S
Stereotact Funct Neurosurg; 1994; 63(1-4):241-5. PubMed ID: 7624640
[TBL] [Abstract][Full Text] [Related]
43. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group.
Wood JR; Green SB; Shapiro WR
J Clin Oncol; 1988 Feb; 6(2):338-43. PubMed ID: 3339397
[TBL] [Abstract][Full Text] [Related]
44. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
Affronti ML; Heery CR; Herndon JE; Rich JN; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Bigner DD; Friedman HS
Cancer; 2009 Aug; 115(15):3501-11. PubMed ID: 19514083
[TBL] [Abstract][Full Text] [Related]
45. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma.
Tsao MN; Mehta MP; Whelan TJ; Morris DE; Hayman JA; Flickinger JC; Mills M; Rogers CL; Souhami L
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):47-55. PubMed ID: 16111571
[TBL] [Abstract][Full Text] [Related]
46. Intracarotid chemotherapy with 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) in 5% dextrose in water in the treatment of malignant glioma.
Johnson DW; Parkinson D; Wolpert SM; Kasdon DL; Kwan ES; Laucella M; Anderson ML
Neurosurgery; 1987 Apr; 20(4):577-83. PubMed ID: 3587550
[TBL] [Abstract][Full Text] [Related]
47. Intra-arterial and intravenous chemotherapy for the treatment of malignant glioma. Preliminary results.
Calvo FA; Pastor MA; Dy C; Alegría E; Antón Aparicio LM; Gil A; Harguindey S; Zubieta JL; Martinez Lage M
Am J Clin Oncol; 1985 Jun; 8(3):200-9. PubMed ID: 4050738
[TBL] [Abstract][Full Text] [Related]
48. Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma.
Buckner JC; Brown LD; Kugler JW; Cascino TL; Krook JE; Mailliard JA; Kardinal CG; Tschetter LK; O'Fallon JR; Scheithauer BW
J Neurosurg; 1995 Mar; 82(3):430-5. PubMed ID: 7861221
[TBL] [Abstract][Full Text] [Related]
49. Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme.
Smith KA; Ashby LS; Gonzalez LF; Brachman DG; Thomas T; Coons SW; Battaglia M; Scheck A
J Neurosurg; 2008 Dec; 109 Suppl():106-17. PubMed ID: 19123896
[TBL] [Abstract][Full Text] [Related]
50. [Role of high-dose chemotherapy with hemopoietic stem-cell support in the treatment of adult patients with high-grade glioma].
Linassier C; Destrieux C; Benboubker L; Alcaraz L; Bergemer-Fouquet AM; Jan M; Calais G; Colombat P
Bull Cancer; 2001 Sep; 88(9):871-6. PubMed ID: 11604360
[TBL] [Abstract][Full Text] [Related]
51. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; Cokgor I; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Regalado LV; Sampson JH; Shafman TD; Wikstrand CJ; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
J Clin Oncol; 2002 Mar; 20(5):1389-97. PubMed ID: 11870184
[TBL] [Abstract][Full Text] [Related]
52. NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.
Ali AN; Zhang P; Yung WKA; Chen Y; Movsas B; Urtasun RC; Jones CU; Choi KN; Michalski JM; Fischbach AJ; Markoe AM; Schultz CJ; Penas-Prado M; Garg MK; Hartford AC; Kim HE; Won M; Curran WJ
J Neurooncol; 2018 Mar; 137(1):39-47. PubMed ID: 29404979
[TBL] [Abstract][Full Text] [Related]
53. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion.
Stummer W; van den Bent MJ; Westphal M
Acta Neurochir (Wien); 2011 Jun; 153(6):1211-8. PubMed ID: 21479583
[TBL] [Abstract][Full Text] [Related]
54. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial.
Westphal M; Ylä-Herttuala S; Martin J; Warnke P; Menei P; Eckland D; Kinley J; Kay R; Ram Z;
Lancet Oncol; 2013 Aug; 14(9):823-33. PubMed ID: 23850491
[TBL] [Abstract][Full Text] [Related]
55. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394.
Grossman SA; O'Neill A; Grunnet M; Mehta M; Pearlman JL; Wagner H; Gilbert M; Newton HB; Hellman R;
J Clin Oncol; 2003 Apr; 21(8):1485-91. PubMed ID: 12697871
[TBL] [Abstract][Full Text] [Related]
56. Treatment of newly diagnosed malignant glioma in the elderly people: new trials that impact therapy.
Chamberlain MC
Int J Clin Pract; 2013 Dec; 67(12):1225-7. PubMed ID: 24246204
[TBL] [Abstract][Full Text] [Related]
57. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001.
Shapiro WR; Green SB; Burger PC; Mahaley MS; Selker RG; VanGilder JC; Robertson JT; Ransohoff J; Mealey J; Strike TA
J Neurosurg; 1989 Jul; 71(1):1-9. PubMed ID: 2661738
[TBL] [Abstract][Full Text] [Related]
58. Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery.
Rostomily RC; Spence AM; Duong D; McCormick K; Bland M; Berger MS
Neurosurgery; 1994 Sep; 35(3):378-88; discussion 388. PubMed ID: 7800129
[TBL] [Abstract][Full Text] [Related]
59. Patterns of Recurrence After Resection of Malignant Gliomas With BCNU Wafer Implants: Retrospective Review in a Single Institution.
Shimato S; Nishizawa T; Ohshima T; Imai T; Goto S; Yamamoto T; Kato K
World Neurosurg; 2016 Jun; 90():340-347. PubMed ID: 26960286
[TBL] [Abstract][Full Text] [Related]
60. Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis.
Salvati M; D'elia A; Frati A; Brogna C; Santoro A; Delfini R
J Neurosurg Sci; 2011 Mar; 55(1):1-6. PubMed ID: 21464805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
